The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR), published in 2023 by CIDRAP with a cadre of global experts, serves as a strategic planning tool to advance research, coordinate funding, and promote stakeholder engagement in R&D for broadly protective coronavirus vaccines. The CVR Initiative, a joint project of CIDRAP and CEPI, monitors and evaluates progress toward the CVR’s strategic goals and milestones. An expert taskforce provides guidance and feedback on the project. Key components of the initiative currently under development that will be added to the CVR website in 2025 include: (1) a landscape database of coronavirus vaccines in development and (2) a dashboard detailing scientific, policy, and regulatory progress towards broadly protective coronavirus vaccine R&D.
To contact the CVR staff, email us at cvr@umn.edu.
CVR Initiative and CVR Development Partners
CVR Initiative: CEPI and CIDRAP
CEPI and CIDRAP list coming soon
CVR Initiative: Taskforce
Taskforce member list coming soon
Original CVR Development Partners
The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota led CVR development, with funding from the Bill & Melinda Gates Foundation and The Rockefeller Foundation. CVR steering group and taskforce members contributed to the development of the CVR by participating in workgroup calls regarding specific topic areas and/or reviewing written drafts of one or more sections of the document.
Steering Group Members
Ralph Baric, PhD, University of North Carolina, USA
Norman Baylor, PhD, Biologics Consulting Group, USA
Bruce Gellin, MD, MPH, Georgetown University School of Medicine (formerly The Rockefeller Foundation), USA
Jennifer Gordon, PhD, NIAID, NIH, USA
Rosalind Hollingsworth, formerly Gates Foundation, USA
Michael Osterholm, PhD, MPH, CIDRAP, University of Minnesota, USA
Stanley Perlman, MD, PhD, University of Iowa, USA
Helen Rees, MB BCHIR (CANTAB), MA (CANTAB), MRCGP, DCH, DSc Medicine (hc), University of the Witwatersrand, South Africa
Melanie Saville, MBBS, MSc, CEPI, USA
Charlotte Weller, PhD, Wellcome Trust, UK
Taskforce Members
Galit Alter, PhD, Harvard University, USA
Dan Barouch, MD, PhD, Beth Israel Deaconess Medical Center, USA
Seth Berkley, MD, Gavi, the Vaccine Alliance, Switzerland
Pamela J. Bjorkman, PhD, California Institute of Technology, USA
Luciana Borio, MD, Council on Foreign Relations, USA
Marco Cavaleri, PhD, EMA, The Netherlands
Rachel K. Chikwamba, PhD, MBA, Council for Scientific and Industrial Research, South Africa
Christopher Chiu, BMBch, PhD, Imperial College London, UK
Cheryl Cohen, MD, PhD, National Institute of Communicable Diseases; University of the Witwatersrand, South Africa
Christopher da Costa, MD, PhD, CEPI, USA
Mark B. Feinberg, MD, PhD, International AIDS Vaccine Institute, USA
Peter B. Gilbert, PhD, Fred Hutchinson Cancer Center, USA
Jonathan Heeney, DVM, PhD, University of Cambridge, UK
Eric Karikari-Boateng, MPharm, formerly Ghana Food and Drugs Authority, Ghana
Wayne Koff, PhD, Human Immunome Project, USA
Marion Koopmans, DVM, PhD, Erasmus University, The Netherlands
Philip Krause, MD, MBA, Consultant (formerly with the US FDA), USA
Teresa Lambe, PhD, Oxford University, UK
Shabir Madhi, PhD, University of the Witwatersrand, South Africa
Jason McLellan, PhD, University of Texas at Austin, USA
Helen McShane, FRCP, PhD, FMedSci, Oxford University, UK
Kayvon Modjarrad, MD, PhD, Pfizer (formerly with Walter Reed Army Institute of Research), USA
Penny Moore, PhD, University of the Witwatersrand, South Africa
Peter Openshaw, MD, PhD, Imperial College London, UK
Peter Paradiso, PhD, Paradiso Biologics Consulting, USA
Malik Peiris, MBBS, DPhil, University of Hong Kong, China
Stanley Plotkin, MD, University of Pennsylvania, USA
Gregory A. Poland, MD, MACP, FRCP (London), Mayo Vaccine Research Group; Mayo Clinic, USA
Andrew J. Pollard, MBBS, PhD, Oxford Vaccine Group, University of Oxford; NIHR Oxford Biomedical Research Center, Oxford, UK
Stacey Schultz-Cherry, PhD, St. Jude Children's Research Hospital, USA
Boitumelo Semete-Makokotlela, PhD, South African Health Products Regulatory Authority, South Africa
Alex Sigal, PhD, African Research Institute, South Africa
Kanta Subbarao, Laval University (formerly WHO Collaborating Centre for Reference and Research on Influenza), Canada
Eric Topol, MD, Scripps Research, USA
Linfa Wang, PhD, Duke Global Health Institute, Duke-NUS Medical School, Singapore
Daniela Weiskopf, PhD, La Jolla Institute for Immunology, USA
E. John Wherry, PhD, University of Pennsylvania, USA
Michael Worobey, DPhil, University of Arizona, USA
CIDRAP Contributing Authors
Cory Anderson, PhD, MPH
Richard Danila, PhD, MPH, Epidemology Consultant
Eve Lackritz, MD
Tabitha Leighton Kazaglis, MPH
Anje Mehr, MPH
Kristine Moore, MD, MPH, CVR Project Director
Julie Ostrowsky, MSc
Angela Ulrich, PhD, MPH
CIDRAP Editorial/Design Staff
Elise Holmes, MPP
Marty Swain
Jim Wappes, CIDRAP Editorial Director